Lumefantrine Co-Artemether

Summary

Lumefantrine Co-Artemether (CHEMBL4297927) is a phase-3 clinical-stage unknown; indicated across 2 conditions including plasmodium falciparum malaria and malaria.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297927
Name	Lumefantrine Co-Artemether
Type	Unknown
Max phase	3

Also known as: Coartem, CPG-56697, Lumefantrine co-artemether, Riamet, LUMEFANTRINE CO-ARTEMETHER

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Plasmodium falciparum malaria	3	MONDO:0005920	EFO:0007444
malaria	2	MONDO:0005136	EFO:0001068

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE2	5
PHASE4	2
PHASE3	2
PHASE1	2
Not specified	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00119145	PHASE4	COMPLETED	Kintampo Trial of Combination Therapy for Malaria
NCT00699920	PHASE4	COMPLETED	Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks
NCT00484900	PHASE3	COMPLETED	Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria
NCT05842954	PHASE3	COMPLETED	Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria
NCT01614964	PHASE2	COMPLETED	Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)
NCT03167242	PHASE2	COMPLETED	Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
NCT03334747	PHASE2	COMPLETED	Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.
NCT03952650	PHASE1/PHASE2	COMPLETED	Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa…
NCT04546633	PHASE2	COMPLETED	Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
NCT04675931	PHASE2	COMPLETED	To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
NCT02627456	PHASE1	COMPLETED	Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali
NCT02942277	PHASE1	COMPLETED	Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali
NCT00513500	Not specified	COMPLETED	Zambia Integrated Management of Malaria and Pneumonia Study
NCT02528279	Not specified	COMPLETED	Relapses in Plasmodium Ovale and Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).